UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of November 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 19 November 2026, London UK
Velzatinib granted Orphan Drug Designation (ODD) in Japan in
GIST
●
Designation
supported by StrateGIST 1 data showing promising anti-tumour
activity and tolerability profile
●
Adds
to US FDA Fast Track Designation and ODDs in the US and
EU
●
Phase
III studies accelerated in first- and second-line GIST
GSK plc (LSE/NYSE: GSK) today announced that velzatinib, a novel,
highly selective KIT inhibitor, has received Orphan Drug
Designation (ODD) from Japan’s Ministry of Health Labour and
Welfare for the treatment of gastrointestinal stromal tumour
(GIST). The ODD was supported by data from the ongoing phase I/Ib
StrateGIST 1 trial in advanced GIST, which showed promising
anti-tumour activity and a promising tolerability
profile.[1]
In addition to the ODD in Japan,
velzatinib has been granted US Food and Drug Administration (FDA)
Fast Track designation, and US and European Union (EU)
ODD.
GSK is accelerating the development of velzatinib, with phase III
trials under way in first- and second-line advanced / metastatic
GIST.[2],[3]
Enrolment in the second-line clinical
trial is tracking ahead of schedule, reflecting strong interest in
velzatinib from the GIST community, with data expected in the
second half of 2027.
Additional data for velzatinib will be shared at the Connective
Tissue Oncology Society (CTOS) Annual Meeting 2026 (18-21 November,
Seoul, South Korea). Seven abstracts will be presented, including
clinical analyses of velzatinib in first- and second-line GIST
by KIT mutation, preclinical research on mutation
coverage and work on translational biomarkers. These data will
further support velzatinib’s development across
different KIT mutations and lines of therapy, where resistance
and tolerability remain significant challenges.
About velzatinib
Velzatinib is a novel, highly selective KIT inhibitor specifically
designed for gastrointestinal stromal tumour (GIST). This
monotherapy targets all clinically relevant primary and key
secondary KIT mutations, addressing a major unmet need in GIST
treatment where tolerability is challenging and resistance arises
from diverse KIT mutations.
About GIST
Gastrointestinal stromal tumour (GIST) is a rare type of cancer
most commonly arising in the stomach and small intestine. Globally,
approximately 80,000 to 120,000 patients are diagnosed with GIST
annually.[4]
80% of GIST cases are driven by
mutations in the KIT gene that lead to the growth, proliferation and
survival of tumour cells (primary or activating mutations in exons
9 and 11).[5]
Additionally, about 90% of patients
treated in the 1st-line develop new KIT mutations (secondary or resistance mutations in
exons 13 and 17) that typically lead to relapse with limited
therapeutic options.[6]
There are no approved tyrosine kinase
inhibitors (TKIs) that inhibit the full spectrum of clinically
relevant primary and secondary mutations in KIT.
In Japan, the age-adjusted annual incidence of GIST is one of the
highest in the world, at approximately 4 per 100,000
people.[7]
While outcomes for people with GIST
have improved over the past two decades, the five-year survival
rate remains significantly lower once the disease has
spread.[8]
An additional phase II trial with
velzatinib – StrateGIST J – is underway in Japan,
evaluating patients whose disease has progressed, or who are
intolerant to available treatment options.[9]
GSK in oncology
GSK is focused on developing differentiated medicines for cancers
where patients continue to face poor outcomes, treatment
resistance, limited options or significant treatment burden. We
focus where advances in science and technology offer the greatest
opportunity to improve outcomes across haematological, lung,
gastrointestinal, genitourinary and gynaecological cancers. Across
multiple modalities, including targeted small molecules,
antibody-drug conjugates (ADCs) and immunotherapies, GSK applies
deep expertise in cancer biology and immune system science to
develop differentiated medicines designed to deliver durable
responses, overcome resistance and reduce treatment
burden.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at www.gsk.com.
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Sarah
Clements
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
Alison
Hunt
|
+1 540
742 3391
|
(Washington
DC)
|
|
|
|
|
|
|
Investor
Relations:
|
James
Dodwell
|
+44 (0)
7881 269066
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Joanna
Tuplin
|
+44 (0)
7788 351650
|
(London)
|
|
|
Sam
Piper
|
+44 (0)
7824 525779
|
(London)
|
|
|
Dan
Smith
|
+44 (0)
7823 523885
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Frannie
DeFranco
|
+1 215
751 3126
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the “Risk
Factors” section in GSK’s Annual Report on Form 20-F
for 2025, and GSK’s Q3 Results for 2026.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
References
[1] Jones RL, Somaiah N, Bauer
S, et al. Velzatinib (IDRX-42) as 1L or 2L therapy for advanced
gastrointestinal stromal tumors (GISTs) by KIT mutation status: A
subset analysis of the phase 1/1b StrateGIST 1 study. Presented at
ASCO Congress 2026. Abstract #11501.
[2] ClinicalTrials.gov. A study of
IDRX-42 (GSK6042981) versus (vs) sunitinib in participants with
gastrointestinal stromal tumors after imatinib therapy. Accessed
November 2026. Available at: https://clinicaltrials.gov/study/NCT07218926
[3] ClinicalTrials.gov. A study to
investigate velzatinib compared with imatinib in adult participants
with previously untreated metastatic and/or unresectable
gastrointestinal stromal tumors (StrateGIST Frontline). Accessed
November 2026. Available at: https://clinicaltrials.gov/study/NCT07585266.
[4] Søreide K, Sandvik OM,
Søreide JA, et al. Global epidemiology of gastrointestinal
stromal tumours (GIST): A systematic review of population-based
cohort studies. Cancer Epidemiol.
2016;40:39-46.
[5] Zhou S, Abdihamid O, Tan F,
et al. KIT mutations and expression: current knowledge and new
insights for overcoming IM resistance in GIST. Cell Commun Signal.
2024;22(1):153.
[6] Serrano C,
Martín-Broto J, Asencio-Pascual JM, et al. 2023 GEIS
Guidelines for gastrointestinal stromal tumors. Ther Adv Med Oncol.
2023;15:17588359231192388
[7] Hirano H, Naito Y, Nishida
T, et al. Epidemiologic features and age-related differences in
management among patients with gastrointestinal stromal tumors in
Japan: A National Cancer Registry Study. Cancer Res Commun.
2025;5(7):1235-1242.
[8]American
Cancer Society. Survival rates for gastrointestinal stromal tumors.
Accessed November 2026. Available at: https://www.cancer.org/cancer/types/gastrointestinal-stromal-tumor/detection-diagnosis-staging/survival-rates.html.
[9] ClinicalTrials.gov. A study of
velzatinib in participants with metastatic and/or
unresectable GIST after imatinib, sunitinib, regorafenib, and
pimitespib. Accessed November 2026. Available at:
https://clinicaltrials.gov/study/NCT07689201
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: November
19, 2026
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|